(Q28186918)

2

0 references

D Moretti

3

0 references

S De Marco

4

0 references

G J Vigilante

5

0 references

A J Cucchiara

6

0 references

K E Ramsey

7

0 references

S Combe

8

0 references

B Rocca

9

0 references

P Theroux

10

0 references

G A FitzGerald

American Journal of Cardiology

11

0 references

language of work or name

English

0 references

publication date

1 August 2001

0 references

published in

0 references

volume

88

0 references

issue

3

0 references

page(s)

236-42

0 references

cites work

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Paired analysis of urinary thromboxane B2 metabolites in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Long-lived enzymatic metabolites of thromboxane B2 in the human circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Measurement of thromboxane metabolites by gas chromatography-mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Glycoprotein IIb/IIIa antagonists: potential induction and detection of drug-dependent antiplatelet antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Assays for heparin-induced thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0

Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901632-0